METABOLIC
Type 2 diabetes + obesity
High chronic disease burden and commercial relevance with multiple opportunities for differentiated small-molecule and incretin-pathway discovery.
INDIA-FIRST · PRIORITY PROGRAMMES
Ten disease areas worth
earning the right to pursue.
Selected with a composite lens of India disease burden, unmet need, demand and fit with BayesPharma’s discovery system. These are research priorities at target-selection stage—not clinical assets, valuation forecasts or guarantees of profitability.
India burdenUnmet needDemandScientific fitEvidence discipline
CARDIOMETABOLIC
Hypertension + heart failure + dyslipidemia
A broad chronic-care opportunity where resistant hypertension, HFpEF biology and residual lipid risk create multiple hypothesis spaces.
ONCOLOGY · INDIA-FIRST
Oral & head-and-neck cancer
An India-relevant oncology priority with room for precision small molecules, resistance-aware combinations and biomarker-linked design.
ONCOLOGY
Breast cancer / triple-negative disease
A specialty programme space focused on aggressive or resistant disease and biomarker-linked synthetic-lethality strategies.
AMR · INDIA-FIRST
Carbapenem-resistant Gram-negative infections
A high-urgency hospital and public-health priority focused on resistant Enterobacterales and Acinetobacter, where new outer-membrane transport mechanisms may bypass legacy antibiotic cross-resistance.
RENAL
Chronic kidney disease + diabetic kidney disease
A growing chronic-care area linked tightly to diabetes and hypertension, with opportunities around inflammation, fibrosis and cardiorenal protection.
RESPIRATORY
COPD + severe asthma
Chronic respiratory disease creates a large India-relevant need for better exacerbation prevention and differentiated add-on therapies.
METABOLIC LIVER
MASH / metabolic liver disease
Metabolic liver disease follows the same obesity, diabetes and dyslipidemia wave and offers multi-parameter opportunities around fat, inflammation and fibrosis.
INFECTIOUS DISEASE
MDR / RR tuberculosis
A critical India-first and global-access challenge where new oral mechanisms and resistance-robust regimens remain strategically important.
VECTOR-BORNE ANTIVIRAL
Dengue antivirals
An India-relevant programme space focused on direct-acting antivirals, pan-serotype activity and early outpatient treatment hypotheses.